We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

28 hedge funds and large institutions have $1.93M invested in AIM ImmunoTech in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $1.86M → $1.93M (+$66.8K)

15% less funds holding

Funds holding: 33 → 28 (-5)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Holders
28
Holders Change
-5
Holders Change %
-15.15%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
7
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$8.87K
2
Renaissance Technologies
Renaissance Technologies
New York
+$7.79K
3
XT
XTX Topco
Cayman Islands
+$5.84K
4
Verition Fund Management
Verition Fund Management
Connecticut
+$3.73K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$663

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$28.8K
2
Citadel Advisors
Citadel Advisors
Florida
-$15K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$11.1K
4
Jane Street
Jane Street
New York
-$9.35K
5
VF
Virtu Financial
New York
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$937K – – –
BlackRock
2
BlackRock
New York
$329K -$3.94K -95 -1%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$166K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$104K +$7.79K +188 +9%
State Street
5
State Street
Massachusetts
$81.5K – – –
Verition Fund Management
6
Verition Fund Management
Connecticut
$80.5K +$3.73K +90 +6%
BCM
7
Bridgeway Capital Management
Texas
$51.3K – – –
Morgan Stanley
8
Morgan Stanley
New York
$40.2K -$28.8K -694 -45%
Northern Trust
9
Northern Trust
Illinois
$40.1K -$166 -4 -0.5%
SWM
10
SeaCrest Wealth Management
New York
$16.5K -$829 -20 -5%
DS
11
DRW Securities
Illinois
$11.3K -$415 -10 -4%
TSS
12
Two Sigma Securities
New York
$10.1K +$8.87K +214 New
CAPTRUST Financial Advisors
13
CAPTRUST Financial Advisors
North Carolina
$9.42K – – –
FWM
14
ForthRight Wealth Management
Georgia
$9.42K – – –
TRCT
15
Tower Research Capital (TRC)
New York
$8.56K -$290 -7 -4%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$7.93K +$663 +16 +11%
XT
17
XTX Topco
Cayman Islands
$6.65K +$5.84K +141 New
CB
18
Community Bank
New York
$6.22K – – –
DBRC
19
D.B. Root & Company
Pennsylvania
$5.68K – – –
TCM
20
Traynor Capital Management
Pennsylvania
$5.55K – – –
HI
21
Hoey Investments
Pennsylvania
$471 – – –
Osaic Holdings
22
Osaic Holdings
Arizona
$470 -$249 -6 -38%
Wells Fargo
23
Wells Fargo
California
$353 +$41 +1 +14%
Fidelity Investments
24
Fidelity Investments
Massachusetts
$245 +$207 +5 New
AF
25
Advisornet Financial
Minnesota
$236 – – –
1
2

AIM Hedge Fund Activity: Q1 2024 in Review

28 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2024, worth a combined $1.93M — up 3.6% from $1.86M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of AIM and 3 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 4 added.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $8.87K. The largest seller was Morgan Stanley, cutting an estimated $28.8K.

  • 28 institutional investors held AIM ImmunoTech (AIM) as of Q1 2024, down from 33 in Q4 2023.
  • Funds reported $1.93M of AIM ImmunoTech stock for Q1 2024, up 3.6% quarter-over-quarter.
  • 3 funds opened new AIM ImmunoTech positions in Q1 2024 and 8 closed out, a net change of -5 holders.
  • The largest AIM ImmunoTech buyer in Q1 2024 was Two Sigma Securities, an estimated $8.87K added.
  • The largest AIM ImmunoTech seller in Q1 2024 was Morgan Stanley, an estimated $28.8K sold.

Based on aggregated 13F filings for Q1 2024.